JP2023510590A5 - - Google Patents
Info
- Publication number
- JP2023510590A5 JP2023510590A5 JP2022543381A JP2022543381A JP2023510590A5 JP 2023510590 A5 JP2023510590 A5 JP 2023510590A5 JP 2022543381 A JP2022543381 A JP 2022543381A JP 2022543381 A JP2022543381 A JP 2022543381A JP 2023510590 A5 JP2023510590 A5 JP 2023510590A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025195186A JP2026032042A (ja) | 2020-01-17 | 2025-11-14 | 組換えａａｖの産生 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062962911P | 2020-01-17 | 2020-01-17 | |
| US62/962,911 | 2020-01-17 | ||
| PCT/US2021/013689 WO2021146591A2 (en) | 2020-01-17 | 2021-01-15 | Recombinant aav production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195186A Division JP2026032042A (ja) | 2020-01-17 | 2025-11-14 | 組換えａａｖの産生 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023510590A JP2023510590A (ja) | 2023-03-14 |
| JPWO2021146591A5 JPWO2021146591A5 (https=) | 2024-01-23 |
| JP2023510590A5 true JP2023510590A5 (https=) | 2024-01-23 |
| JP7846625B2 JP7846625B2 (ja) | 2026-04-15 |
Family
ID=76864730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543381A Active JP7846625B2 (ja) | 2020-01-17 | 2021-01-15 | 組換えａａｖの産生 |
| JP2025195186A Pending JP2026032042A (ja) | 2020-01-17 | 2025-11-14 | 組換えａａｖの産生 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195186A Pending JP2026032042A (ja) | 2020-01-17 | 2025-11-14 | 組換えａａｖの産生 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048994A1 (https=) |
| EP (1) | EP4090750A4 (https=) |
| JP (2) | JP7846625B2 (https=) |
| CN (1) | CN115315518A (https=) |
| AU (1) | AU2021207683A1 (https=) |
| CA (1) | CA3162520A1 (https=) |
| IL (1) | IL294775A (https=) |
| WO (1) | WO2021146591A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4189077A1 (en) | 2020-07-30 | 2023-06-07 | Shape Therapeutics Inc. | Stable cell lines for inducible production of raav virions |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| WO2024129882A1 (en) * | 2022-12-14 | 2024-06-20 | Astellas Gene Therapies, Inc. | Compositions and methods for improved production of adeno-associated viral particles |
| AU2024223271A1 (en) * | 2023-02-17 | 2025-09-18 | Synplogen Co., Ltd. | Itr-rep gene complex |
| EP4527938A1 (en) * | 2023-09-22 | 2025-03-26 | LenioBio GmbH | Method for cell-free polypeptide synthesis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| EP2848253A1 (en) * | 2006-06-19 | 2015-03-18 | Asklepios Biopharmaceutical, Inc. | Modified factor VIII and factor IX genes and vectors for gene therapy |
| WO2008105931A2 (en) * | 2006-09-15 | 2008-09-04 | Medimmune Vaccines, Inc. | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
| GB0901593D0 (en) * | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
| US9441206B2 (en) * | 2011-10-28 | 2016-09-13 | The University Of North Carolina At Chapel Hill | Cell line for production of adeno-associated virus |
| EP3039129B1 (en) * | 2013-08-30 | 2018-06-27 | Amgen Inc. | High titer recombinant aav vector production in adherent and suspension cells |
| AU2016362317B2 (en) * | 2015-12-01 | 2023-03-16 | Spark Therapeutics, Inc. | Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use |
| EP3810782A2 (en) * | 2018-06-22 | 2021-04-28 | Asklepios Biopharmaceutical, Inc. | Vectors for gene delivery that persist within cells |
-
2021
- 2021-01-15 WO PCT/US2021/013689 patent/WO2021146591A2/en not_active Ceased
- 2021-01-15 AU AU2021207683A patent/AU2021207683A1/en active Pending
- 2021-01-15 CA CA3162520A patent/CA3162520A1/en active Pending
- 2021-01-15 CN CN202180023263.2A patent/CN115315518A/zh active Pending
- 2021-01-15 EP EP21741128.9A patent/EP4090750A4/en active Pending
- 2021-01-15 US US17/793,196 patent/US20230048994A1/en active Pending
- 2021-01-15 JP JP2022543381A patent/JP7846625B2/ja active Active
- 2021-01-15 IL IL294775A patent/IL294775A/en unknown
-
2025
- 2025-11-14 JP JP2025195186A patent/JP2026032042A/ja active Pending